2,3,5-Trimethyl-bromanisol | 103323-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,3,5-Trimethyl-bromanisol
• 英文别名: 2-methoxy-3,4,6-trimethylbromobenzene；2-bromo-3,5,6-trimethylanisole；2-bromo-3-methoxy-1,4,5-trimethylbenzene
• CAS: 103323-59-7
• 化学式: C₁₀H₁₃BrO
• 分子量: 229.117
• InChiKey: XLGBKYFIVQZUDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,3,5-Trimethyl-bromanisol 在 palladium on activated charcoal 正丁基锂 、 氢溴酸 、 氢气 、 硝酸 、 乙酸酐 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 22.0h， 生成 (+)-2,2,4,6,7-pentamethyl-3-(4-methylphenyl)-2,3-dihydro-1-benzofuran-5-amine
  参考文献：
  名称：

  5-Aminocoumarans:  Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects against Central Nervous System Trauma and Ischemia

  摘要：

  A series of 2,3-dihydro-5-benzofuranamines (5-aminocoumarans) were developed for the treatment of traumatic and ischemic central. nervous system (CNS) injury. Compounds within this class were extremely effective inhibitors of lipid peroxidation in vitro and antagonized excitatory behavior coupled with peroxidative injury induced by spinal intrathecal injection of FeCl2 (mouse-FeCl2-it assay) in vivo. Selected compounds were tested for antagonistic activity on methamphetamine (MAP)-induced hypermotility resulting from dopamine release in the mouse brain. Among the compounds synthesized, compound 26n (2,3-dihydro-2,4,6,7-tetramethyl-2-[(4-phenyl-1-piperidinyl)meth]-5-benzofuranamine) exhibited potent effects in these assays (inhibition of lipid peroxidation, IC50 = 0.07 mu M; mouse-FeCl2-it assay, ID50 = 10.4 mg/kg, po; MAP-induced hypermotility, 98% inhibition, 10 mg/kg, ip). The S-(+)-form of compound 26n dihydrochloride (TAK-218), which has 30 times more potent antagonistic activity on MAP-induced hypermotility than the R-(-)-form, improved more significantly the survival rate in the cerebral ischemia model (rat, 1-3 mg/kg, ip) during the period of 1-14 days after ischemia and decreased functional disorders in the traumatic brain injury model (rat, 0.1-1 mg/kg, ip) 3-14 days after injury. These results imply a role for dopamine in deterioration of CNS function after ischemic and traumatic injury. TAK-218 is a promising compound for the treatment of stroke and CNS trauma and is now under clinical investigation.

  DOI：

  10.1021/jm960411j
• 作为产物：
  描述：

  2,3,5-三甲基苯酚 、 叔丁胺 、 碘甲烷 在 溴 作用下， 以 N-甲基乙酰胺 、 二氯甲烷 、 甲苯 为溶剂， 生成 2,3,5-Trimethyl-bromanisol
  参考文献：
  名称：

  Aminocoumaran derivatives, their production and use

  摘要：

  一种一般式（I）的新型氨基香豆素衍生物：##STR1##其中R.sup.1和R.sup.2是氢原子、酰基、烷氧羰基、脂肪基或芳香基；R.sup.3、R.sup.4和R.sup.5是可选酰化的羟基、可选取代的氨基、烷氧基或脂肪基，或者R.sup.3、R.sup.4和R.sup.5中的两个可以连接在一起形成一个碳环基团；R.sup.6和R.sup.7是脂肪基，其中至少一个在α-位置有一个亚甲基基团；R.sup.8和R.sup.9是氢原子或脂肪基或芳香基，或其盐，用于预防和治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。

  公开号：

  US05376681A1

文献信息

• Benzofuran derivatives, their production and use
  申请人：——

  公开号：US20020160996A1

  公开（公告）日：2002-10-31

  Compounds represented by the formula: 1 wherein R 1 and R 2 are hydrogen atom, a hydrocarbon group or a heterocyclic group, or R 1 and R 2 may form, together with the adjacent carbon atom, a 3- to 8-membered homocyclic or heterocyclic ring, W indicates (i) a group represented by the formula: 2 wherein ring B indicates a 5- to 7-membered ring, or (ii) a group represented by the formula: 3 wherein R 4 indicates (1) an aliphatic hydrocarbon group, which may be substituted with an aromatic group, or (2) an acyl group containing an aromatic group, R 5 is hydrogen atom, a C 1-6 alkyl, or an acyl group, provided that, when W is Wa, R 3 is hydrogen atom, a hydrocarbon group or a heterocyclic group, when W is Wb, R 3 indicates a C 6-14 aryl group, or salts thereof or prodrugs thereof have an excellent action to inhibit neurodegeneration and the like as well as an excellent brain penetrability and are low in the toxicity, thereby being useful as prophylactic or therapeutic drugs for nerve degenerative diseases and the like.

  由以下公式代表的化合物： 其中 R1 和 R2 是氢原子、烃基或杂环基，或者 R1 和 R2 可以与相邻的碳原子一起形成 3 至 8 个成员的同环或杂环环，W 表示 (i) 由以下公式代表的基团： 其中环 B 表示一个 5 至 7 个成员的环，或者 (ii) 由以下公式代表的基团： 其中 R4 表示 (1) 可以用芳香基取代的脂肪烃基，或者 (2) 含有芳香基的酰基，R5 是氢原子、C1-6 烷基或酰基，提供当 W 是 Wa 时，R3 是氢原子、烃基或杂环基，当 W 是 Wb 时，R3 表示一个 C6-14 芳基，或其盐或前药具有优异的抑制神经退行性等作用，以及出色的脑透过性，毒性低，因此可用作预防或治疗神经退行性疾病等的药物。
• Intermediates for pharmaceutically useful aminocoumaran derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05594154A1

  公开（公告）日：1997-01-14

  A novel aminocoumaran derivative of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

  一种新型氨基香豆素衍生物的一般式为（I）：##STR1## 其中，R.sup.1和R.sup.2是氢原子、酰基、烷氧羰基、脂肪基或芳基；R.sup.3、R.sup.4和R.sup.5是一个可选酰化的羟基、可选取代的氨基、烷氧基或脂肪基，或R.sup.3、R.sup.4和R.sup.5中的两个可连接在一起形成碳环基；R.sup.6和R.sup.7是脂肪基，其中至少一个在α位上有一个亚甲基；R.sup.8和R.sup.9是氢原子或脂肪基或芳基，或其盐，可用于预防和治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。
• Method of using aminocoumaran derivatives for treating cerebrovascular
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05478844A1

  公开（公告）日：1995-12-26

  A novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least: one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

  一种新型氨基香豆素衍生物，其通式为(I)：##STR1## 其中R.sup.1和R.sup.2为氢原子、酰基、烷氧基羰基、脂肪基或芳香族基；R.sup.3、R.sup.4和R.sup.5为可选的酰化羟基、可选的取代氨基、烷氧基或脂肪基，或者R.sup.3、R.sup.4和R.sup.5中的两个可以连接在一起形成一个环状碳骨架；R.sup.6和R.sup.7为脂肪基，至少其中一个在α-位上有一个亚甲基；R.sup.8和R.sup.9为氢原子、脂肪基或芳香族基，或其盐，用于治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。
• Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
  申请人：——

  公开号：US20040034049A1

  公开（公告）日：2004-02-19

  An agent for promoting the proliferation or differentiation of a stem cell and/or neural progenitor cell, comprising a compound represented by Formula: 1 wherein each of R 1 and R 2 is H, a hydrocarbon group or a heterocyclic group, or taken together with the adjacent carbon atom to form a ring, R 3 is H, a hydrocarbon group or a heterocyclic group, W is a group represented by Formula: 2 wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted 5- to 7-membered nitrogen-containing heterocyclic ring, R 4 is an acyl group having an aliphatic hydrocarbon group, which is substituted by an aromatic group and may have a further substitutent, or aromatic group, R 5 is H, C 1-6 alkyl or acyl, R 4c is an aromatic group, an aliphatic hydrocarbon group or acyl, and X is O or S; Y is O, S or NH, Ring C is an optionally substituted benzene ring, or a salt or prodrug thereof is provided.

  一种用于促进干细胞和/或神经前体细胞增殖或分化的药剂，包括由公式1表示的化合物，其中R1和R2中的每一个是H、烃基或杂环基，或与相邻的碳原子结合形成环，R3是H、烃基或杂环基，W是由公式2表示的基团，其中环A是可选取代的苯环，环B是可选取代的含氮5-至7元杂环环，R4是取代芳香基的脂肪烃基的酰基，可以有进一步的取代基，或芳香基，R5是H、C1-6烷基或酰基，R4是芳香基、脂肪烃基或酰基，X是O或S；Y是O、S或NH，环C是可选取代的苯环，或其盐或前药。
• Intermediates for the preparation of aminocoumaran derivatives
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05770772A1

  公开（公告）日：1998-06-23

  Disclosed are intermediates for the preparation of novel aminocoumaran derivatives of the general formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are a hydrogen atom, an acyl group, an alkoxycarbonyl group, an aliphatic group or aromatic group; R.sup.3, R.sup.4 and R.sup.5 are an optionally acylated hydroxyl, optionally substituted amino group, alkoxy group or aliphatic group, or two of R.sup.3, R.sup.4 and R.sup.5 may be linked together to form a carbocyclic group; R.sup.6 and R.sup.7 are an aliphatic group and at least one of them has a methylene group at the .alpha.-position; R.sup.8 and R.sup.9 are a hydrogen atom or an aliphatic group or aromatic group, or a salt thereof is useful for medicines for preventing and treating various diseases such as arterial sclerosis, hepatopathy, cerebrovascular diseases and the like.

  本发明涉及一种制备新型氨基香豆素衍生物的中间体，其一般式为(I)：##STR1## 其中，R.sup.1和R.sup.2是氢原子、酰基、烷氧羰基、脂肪基或芳香基；R.sup.3、R.sup.4和R.sup.5是可选酰化的羟基、可选取代的氨基、烷氧基或脂肪基，或R.sup.3、R.sup.4和R.sup.5中的两个可以连接在一起形成碳环基；R.sup.6和R.sup.7是脂肪基，其中至少一个在α-位上有一个亚甲基；R.sup.8和R.sup.9是氢原子或脂肪基或芳香基，或其盐，适用于预防和治疗各种疾病，如动脉硬化、肝病、脑血管疾病等。